Clinical trials: Adult Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Effects of Transcranial Photobiomodulation in ADHD
The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion…
- Trial name
- NCT07203092
- Testing
- Active transcranial photobiomodulation
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Francisco Gonzalez-Lima, PhD
Attention Deficit Disorder With Hyperactivity
Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder
This study will determine whether the drug betahistine increases focus and causes side effects in people with attention deficit hyperactivity disorder.
- Trial name
- NCT00829881
- Testing
- Betahistine Hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- P2D, Inc.
ADHD
Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment
The objective of this research is to use functional magnetic resonance imaging (fMRI) with a neuropsychological task to test the prefrontal mechanism of action of the medical food Vayarin.
- Trial name
- VAYA-fMRI (NCT02473419)
- Testing
- Vayarin
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
CBT for Adult Inmates With ADHD
Background Recent literature suggests that ADHD is a risk factor for the development of antisocial behavior that is more severe and persistent than in community and other psychiatric populations.
- Trial name
- NCT06080373
- Testing
- PROBECO, Formulation-based cognitive behavioral therapy
- Volunteers
- 111 people
- Sponsor
- Universidad Europea de Valencia
Attention Deficit Hyperactivity Disorder (ADHD), Substance-related Disorder
Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment
Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences.
- Trial name
- ATTenTIFF (NCT06858527)
- Testing
- TAU+integrated group CBT
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Attention Deficit Disorder
Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill
Randomized clinical trial in which individuals who have been diagnosed with ADHD and are regularly treated with Methylphenidate will be test for cognitive performance and will be randomly examined in the following four…
- Trial name
- NCT05243186
- Testing
- Treadmill workstation, Methylphenidate
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ariel University
ADHD
A Comparison of Group Cognitive Behavioural Therapy (CBT) and Structured Activity Group for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Many adults with attention deficit hyperactivity disorder (ADHD) experience difficulties with inattention, planning, impulsivity and emotion regulation that impacts work and social life negatively also after treatment with…
- Trial name
- NCT07834437
- Testing
- Group CBT based on DBT-skills training, Activity group
- Where
- 2 sites in Sweden
- Volunteers
- 120 people
- Sponsor
- Region Stockholm
Cerebrovascular Accident, Transient Ischemic Attack
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 January 2003 through 31…
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Trial name
- NCT00634439
- Testing
- atomoxetine, Stimulants, No intervention (general population)
- Where
- United States
- Volunteers
- 72,000 people
- Sponsor
- Eli Lilly and Company
Adult Attention Deficit Hyperactivity Disorder
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
- Trial name
- NCT03324581
- Testing
- OPC-64005, Atomoxetine
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD465 in Adults With ADHD
The purpose of the study is to evaluate how safe and how well SPD465 works compared to placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration of clinical benefit.
- Trial name
- NCT00202605
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Shire
ADHD, Smoking
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation…
- Trial name
- NCT00253747
- Testing
- Osmotic-Release Methylphenidate
- Where
- 6 sites in United States
- Volunteers
- 255 people
- Sponsor
- University of Cincinnati
Attention Deficit Hyperactivity Disorder
A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators
The purpose of this study is to determine whether SPD465 is safe and effective in the treatment of ADHD in young adult drivers after a duration of 16 hours.
- Trial name
- NCT00458445
- Testing
- SPD465
- Where
- United States
- Sponsor
- Shire
ADHD
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
The primary objective of the study is to assess the efficacy and tolerability of a 12-week trial of memantine hydrochloride administered twice daily in 20 adults (ages 18-55) with ADHD and ADHD NOS.
- Trial name
- NCT00586573
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
ADHD, Dyslexia
A Strength-Based Intervention to Improve Job Interview Skills in Neurodiverse Young Adults
the investigators are looking to evaluate the effectiveness of a strength-based program in improving job interview skills in neurodiverse young adults.
- Conditions
- ADHD, Dyslexia, Learning Disabilities
- Trial name
- NCT06479850
- Testing
- KF-STRIDE®
- Volunteers
- 50 people
- Sponsor
- Kessler Foundation
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning…
- Trial name
- NCT02096952
- Testing
- Methylphenidate extended-release liquid formulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit/Hyperactivity Disorder (ADHD)
To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.
An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study in healthy adult human subjects under fasting conditions.
- Trial name
- NCT07098585
- Testing
- Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Volunteer, Attention Deficit Hyperactivity Disorder
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)
This study will explore the brain in men with and without attention deficit hyperactivity disorder (ADHD). It will use positron emission tomography (PET) and magnetic resonance imaging (MRI) to study brain function and nerve cell…
- Trial name
- NCT00397748
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Mental Health (NIMH)
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD.
- Trial name
- Atom (NCT00218543)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
ADHD
Efficacy of an Occupational Intervention for Improving Quality of Work Life in Adults Living With ADHD
An adaptation of the Minds@Work intervention to improve quality of life at work for adults living with attention deficit disorder with/without hyperactivity (ADHD), following a group format.
- Trial name
- NCT06774378
- Testing
- Minds@Work-ADHD-Quality of Life, Minimal contact
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Université du Québec a Montréal
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to…
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00334880
- Testing
- NRP104
- Where
- 48 sites in United States
- Volunteers
- 420 people
- Sponsor
- New River Pharmaceuticals